http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Koh, Won-Jung,Jeong, Byeong-Ho,Jeon, Kyeongman,Park, Hye Yun,Kim, Su-Young,Huh, Hee Jae,Ki, Chang-Seok,Lee, Nam Yong,Shin, Sung Jae,Daley, Charles L. American Society for Microbiology 2015 Antimicrobial Agents and Chemotherapy Vol.59 No.8
<P>Intermittent three-times-weekly antibiotic therapy is recommended for the initial treatment of patients with noncavitary nodular bronchiectatic <I>Mycobacterium avium</I> complex lung disease. Although some experts recommend switching from intermittent to daily therapy for patients whose sputum has persistent positive cultures after intermittent therapy, the clinical efficacy of these modifications is unknown. Of 20 patients whose sputum had persistent positive cultures after 12 months of intermittent antibiotic therapy, specimens from 6 patients (30%) achieved a negative culture after a change to daily therapy.</P>
대만 등줄쥐 (Apodemus agrarius insulaemus)의 유전자다양성: 미토콘드리아 DNA Cytochrome b 유전자 염기서열 분석
고흥선, 장경희, Pei Jen Shaner, 이배근, 양병국, 허선욱 忠北大學校部設基礎科學硏究所 2012 自然科學硏究 Vol.26 No.-
Taiwan의 섬 아종인 A. a. insulaemus의 유전자다양성을 연구하기 위하여, 동아시아의 18개 지역에서 잡은 A. agrarius 네 아종 45 표본의 cytochrome b 염기서열 (1,140 bp)을 얻은 후에, 이들 염기서열들 을 GenBank에서 얻은 등줄쥐 여섯 아종의 염기서열과 비교하였다. Apodemus agrarius에서 두 개의 clades가 파악되었는데, 하나는 대만 clade (섬아종인 insulaemus)이고, 다른 하나는 대륙 clade (유라시 아 대륙의 다섯 아종인 coreae, mantchuricus, pallidior, ningpoensis, and agrarius)였다. 따라서 대 만의 A. a. insulaemus는 유라시아의 대륙 아종들과 유전적인 차이를 보인다고 규명하였다. 또한 대만의 insulaemus는 등줄쥐내의 phylogroup으로 밝혀졌음으로, 본 연구결과들을 확인하기 위한 핵 및 미토콘드리 아 DNA marker를 이용한 분석이 필요하게 되었다.
Koh, Won-Jung,Jeong, Byeong-Ho,Jeon, Kyeongman,Kim, Su-Young,Park, Kyoung Un,Park, Hye Yun,Huh, Hee Jae,Ki, Chang-Seok,Lee, Nam Yong,Lee, Seung-Heon,Kim, Chang Ki,Daley, Charles L.,Shin, Sung Jae,Kim, American College of Chest Physicians 2016 Chest Vol. No.
<P>CONCLUSIONS: Oral macrolide therapy after an initial 2-week course of combination antibiotics might be effective in most patients with M massiliense lung disease.</P>
Do we need colonoscopy verification in patients with fundic gland polyp?
( Hee Sook Lee ),( Younjeong Choi ),( Ja Young Jung ),( Young Jun Sung ),( Dong Won Ahn ),( Ji Bong Jeong ),( Byeong Gwan Kim ),( Kook Lae Lee ),( Seong Joon Koh ),( Ji Won Kim ) 대한장연구학회 2016 Intestinal Research Vol.14 No.2
Background/Aims: The aim of this study was to evaluate the prevalence of colorectal neoplasia in subjects with fundic gland polyps (FGPs) and the relationship between FGPs and colorectal neoplasia in Korea. Methods: We analyzed 128 consecutive patients with FPGs who underwent colonoscopy between January 2009 and December 2013. For each case, age- (±5 years) and sex-matched controls were identified from among patients with hyperplastic polyps, gastric neoplasms, and healthy controls. Clinical characteristics were reviewed from medical records, colonoscopic findings, pathologic findings, and computed tomography images. The outcome was evaluated by comparison of advanced colonic neoplasia detection rates. Results: Of the 128 patients, seven (5.1%) had colon cancers and seven (5.1%) had advanced adenomas. A case-control study revealed that the odds of detecting a colorectal cancer was 3.8 times greater in patients with FGPs than in the age- and sex-matched healthy controls (odds ratio [OR], 3.80; 95% confidence interval [CI], 1.09-13.24; P =0.04) and 4.1 times greater in patients with FGPs than in healthy controls over 50 years of age (OR, 4.10; 95% CI, 1.16-14.45; P =0.04). Among patients with FGPs over 50 years old, male sex (OR, 4.83; 95% CI, 1.23-18.94; P =0.02), and age (OR, 9.90; 95% CI, 1.21-81.08; P =0.03) were associated with an increased prevalence of advanced colorectal neoplasms. Conclusions: The yield of colonoscopy in colorectal cancer patients with FGPs was substantially higher than that in average-risk subjects. Colonoscopy verification is warranted in patients with FGPs, especially in those 50 years of age or older. (Intest Res 2016;14:172-177)
( Byeong Ho Jeong ),( Kyeongman Jeon ),( Hye Yun Park ),( Su Young Kim ),( Hee Jae Huh ),( Chang Seok Ki ),( Nam Yong Lee ),( Sung Jae Shin ),( Won Jung Koh ) 대한내과학회 2014 대한내과학회 추계학술발표논문집 Vol.2014 No.1
Background: Although intermittent, three-times-weekly, therapy is recommended for initial treatment for the non-cavitary nodular bronchiectatic Mycobacterium avium complex (MAC) lung disease, supporting data are limited. This study is conducted to evaluate the clinical effi cacy of intermittent therapy compared with daily therapy for the nodular bronchiectatic MAC lung disease. Methods: A retrospective cohort study of 217 patients with treatment-naive non-cavitary nodular bronchiectatic MAC lung disease. These patients received daily (n = 99) or intermittent therapy (n = 118) which included clarithromycin or azithromycin, rifampin, and ethambutol. Results: Modifi cation of initial antibiotic therapy occurred more frequently in daily therapy group than in intermittent therapy group (46% vs. 21%, P < 0.001). In particular, ethambutol was more frequently discontinued in daily therapy group than in intermittent therapy group (24% vs. 1%, P < 0.001). However, rates of symptomatic improvement, radiographic improvement, and sputum culture conversion were not different between two groups (daily therapy vs. intermittent therapy; 75% vs. 82%, P = 0.181; 68% vs. 73%, P = 0.402; 76% vs. 67%, P = 0.154; respectively). In addition, adjusted proportion of sputum culture conversion rates was similar between daily therapy group (71.3%, 95% confidence interval [CI] 59.1-81.1%) and intermittent therapy group (73.6%, 95% CI 62.9-82.2%, P = 0.785). Conclusions: These results suggested that intermittent three-times-weekly therapy with macrolide, rifampin, and ethambutol is a reasonable initial treatment regimen to patients with non-cavitary nodular bronchiectatic MAC lung disease.
Mycobacterial Characteristics and Treatment Outcomes in <i>Mycobacterium abscessus</i> Lung Disease
Koh, Won-Jung,Jeong, Byeong-Ho,Kim, Su-Young,Jeon, Kyeongman,Park, Kyoung Un,Jhun, Byung Woo,Lee, Hyun,Park, Hye Yun,Kim, Dae Hun,Huh, Hee Jae,Ki, Chang-Seok,Lee, Nam Yong,Kim, Hong Kwan,Choi, Yong So Oxford University Press 2017 Clinical Infectious Diseases Vol. No.
<P><B>Summary.</B></P><P>Several mycobacterial characteristics, including colony morphotype, susceptibility to macrolide antibiotics, and T28C substitution in the <I>erm</I>(41) gene, are helpful in predicting the treatment responses of patients with <I>Mycobacterium abscessus</I> lung disease. Treatment failures and recurrences are frequently caused by reinfection.</P><P><B>Background.</B></P><P>Treatment outcomes of patients with <I>Mycobacterium abscessus</I> subspecies <I>abscessus</I> lung disease are poor, and the microbial characteristics associated with treatment outcomes have not been studied systematically. The purpose of this study was to identify associations between microbial characteristics and treatment outcomes in patients with <I>M. abscessus</I> lung disease.</P><P><B>Methods.</B></P><P>Sixty-seven consecutive patients with <I>M. abscessus</I> lung disease undergoing antibiotic treatment for ≥12 months between January 2002 and December 2012 were included. Morphotypic and genetic analyses were performed on isolates from 44 patients.</P><P><B>Results.</B></P><P>Final sputum conversion to culture negative occurred in 34 (51%) patients. Compared to isolates from 24 patients with persistently positive cultures, pretreatment isolates from 20 patients with final negative conversion were more likely to exhibit smooth colonies (9/20, 45% vs 2/24, 8%; <I>P</I> = .020), susceptibility to clarithromycin (7/20, 35% vs 1/24, 4%; <I>P</I> = .015), and be of the C28 sequevar with regard to the <I>erm</I>(41) gene (6/20, 30% vs 1/24, 4%; <I>P</I> = .035). <I>Mycobacterium abscessus</I> lung disease recurred in 5 (15%) patients after successful completion of antibiotic therapy. Genotypic analysis revealed that most episodes (22/24, 92%) of persistently positive cultures during antibiotic treatment and all cases of microbiologic recurrence after treatment completion were caused by different <I>M. abscessus</I> genotypes within a patient.</P><P><B>Conclusions.</B></P><P>Precise identification to the subspecies level and analysis of mycobacterial characteristics could help predict treatment outcomes in patients with <I>M. abscessus</I> lung disease. Treatment failures and recurrences are frequently associated with multiple genotypes, suggesting reinfection.</P><P><B>Clinical Trials Registration.</B></P><P>NCT00970801.</P>
( Byeong Ho Jeong ),( Kyeong Man Jeon ),( Hye Yun Park ),( Su Young Kim ),( Hee Jae Huh ),( Chang Seok Ki ),( Nam Yong Lee ),( Sung Jae Shin ),( Won Jung Koh ) 대한결핵 및 호흡기학회 2014 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.118 No.-
Background: Although intermittent, three-times-weekly, therapy is recommended for initial treatment for the non-cavitary nodular bronchiectatic Mycobacterium avium complex (MAC) lung disease, supporting data are limited. This study is conducted to evaluate the clinical efficacy of intermittent therapy compared with daily therapy for the nodular bronchiectatic MAC lung disease. Methods: A retrospective cohort study of 217 patients with treatment-naive non-cavitary nodular bronchiectatic MAC lung disease. These patients received daily (n = 99) or intermittent therapy (n = 118) which included clarithromycin or azithromycin, rifampin, and ethambutol. Results: Modification of initial antibiotic therapy occurred more frequently in daily therapy group than in intermittent therapy group (46% vs. 21%, P < 0.001). In particular, ethambutol was more frequently discontinued in daily therapy group than in intermittent therapy group (24% vs. 1%, P < 0.001). However, rates of symptomatic improvement, radiographic improvement, and sputum culture conversion were not different between two groups (daily therapy vs. intermittent therapy; 75% vs. 82%, P = 0.181; 68% vs. 73%, P = 0.402; 76% vs. 67%, P = 0.154; respectively). In addition, adjusted proportion of sputum culture conversion rates was similar between daily therapy group (71.3%, 95% confidence interval [CI] 59.1-81.1%) and intermittent therapy group (73.6%, 95% CI 62.9-82.2%, P = 0.785). Conclusions: These results suggested that intermittent three-times-weekly therapy with macrolide, rifampin, and ethambutol is a reasonableinitial treatment regimen to patients with non-cavitary nodular bronchiectatic MAC lung disease.
Outcomes of pulmonary MDR-TB: impacts of fluoroquinolone resistance and linezolid treatment
Jeong, Byeong-Ho,Jeon, Kyeongman,Park, Hye Yun,Kwon, O Jung,Lee, Kyung Soo,Kim, Hong Kwan,Choi, Yong Soo,Kim, Jhingook,Huh, Hee Jae,Lee, Nam Yong,Koh, Won-Jung Oxford University Press 2015 The Journal of antimicrobial chemotherapy Vol.70 No.11
<P><B>Objectives</B></P><P>Fluoroquinolones (FQs) are the most important second-line drugs for MDR-TB treatment. Therapeutic options for FQ-resistant (FQ-R) MDR/XDR-TB are very limited. The purpose of the present study was to determine treatment outcomes and risk factors associated with unfavourable outcomes of MDR/XDR-TB, focusing on the impacts of FQ-R status and linezolid treatment.</P><P><B>Methods</B></P><P>This was a retrospective cohort study of 337 MDR-TB patients, including 144 (42.7%) FQ-R MDR/XDR-TB cases. Treatment outcomes were evaluated according to WHO 2013 recommendations.</P><P><B>Results</B></P><P>Later-generation FQs such as levofloxacin or moxifloxacin were given to 331 (98.2%) patients. Overall, favourable outcomes were achieved in 272 (80.7%) patients. FQ-R second-line injectable drug-susceptible MDR [adjusted OR (aOR) 4.299, 95% CI 1.239–14.916, <I>P</I> = 0.015] and XDR status (aOR 6.294, 95% CI 1.204–32.909, <I>P</I> = 0.024) were independently associated with unfavourable outcomes. However, FQ-susceptible (FQ-S) second-line injectable drug-resistant MDR status was not associated with unfavourable outcomes (aOR 1.814, 95% CI 0.314–10.485, <I>P</I> = 0.999). Favourable treatment outcomes were more frequent in FQ-R MDR/XDR-TB patients who received linezolid (82.8%) compared with those who did not receive linezolid (58.1%, <I>P</I> = 0.002). When FQ-R MDR/XDR-TB treatment without linezolid was used as a reference, the addition of linezolid was associated with favourable outcomes (aOR 4.081, 95% CI 1.237–13.460, <I>P</I> = 0.017), comparable to those for FQ-S MDR-TB (aOR 4.341, 95% CI 1.470–12.822, <I>P</I> = 0.005).</P><P><B>Conclusions</B></P><P>Later-generation FQs could improve treatment outcomes of patients with MDR-TB. Linezolid should be considered for inclusion in FQ-R MDR/XDR-TB treatment regimens.</P>